BON-1 is a human serotonin-producing endocrine pancreatic tumor (EPT) cell line, which has been used for various studies of tumorigenesis and treatment. Because its genotype, phenotype and degree of differentiation may underlie events that are instrumental to the development of endocrine tumors and, moreover, may vary between labs and over time, we decided to comprehensively characterize the chromosomal constitution of BON-1 by applying conventional GTG-banding, spectral karyotyping (SKY), comparative genomic hybridization (CGH) and fluorescence in situ hybridization (FISH). BON-1 cells proved to be hyperdiploid containing a modal chromosome number of 57 (range 56–64). SKY identified a stemline containing 6 clonal aberrations including del(1p), t(9;12)del(9p)x2, der(10)t(5;10), der(19)t(8;19), der(14)t(9;14)t(9;10), and a sideline harboring an additional del(12q). CGH and FISH confirmed the SKY results and, in addition, highlighted the chromosomal regions involved in the rearrangements. Moreover, they identified a homozygous deletion of the key tumor suppressor genes CDKN2A and CDKN2B at 9p21.3, in accordance with absence of p16INK4A and p14ARF expression as revealed by immunocytochemistry. Apart from deregulation of the cell cycle and p53 pathway this finding indicates escape from replicative senescence (induced by mutated NRAS) and detachment-induced apoptosis as molecular mechanisms underlying the tumorigenesis of BON-1 cells. Immunostaining results for p53, MDM2 and pRb expression were consistent with previously published data using Western analysis. In conclusion, we provide here a comprehensive cytogenetic profile of BON-1. This cell line harbors both numerical and structural genomic alterations indicative for malignant EPTs.

Keywords:
BON-1, Endocrine pancreatic tumor, Carcinoid, Spectral karyotyping, Comparative genomic hybridization, p16INK4A
1.
DeLellis RA, Lloyd RV, Heitz PU, Eng C: World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of Endocrine Organs. Lyon, IARC Press, 2004.
2.
Schussheim DH, Skarulis MC, Agarwal SK, Simonds WF, Burns AL, Spiegel AM, Marx SJ: Multiple endocrine neoplasia type 1: new clinical and basic findings. Trends Endocrin Metab 2001;12:173–178.
3.
Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, Emmert-Buck MR, Debelenko LV, Zhuang Z, Lubensky IA, Liotta LA, Crabtree JS, Wang Y, Roe BA, Weisemann J, Boguski MS, Agarwal SK, Kester MB, Kim YS, Heppner C, Dong Q, Spiegel AM, Burns AL, Marx SJ: Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997;276:404–407.
4.
Agarwal S, Kennedy P, Scacheri P, Novotny E, Hickman, Cerrato A, Rice T, Moore J, Rao S, Ji Y, Mateo C, Libutti S, Oliver B, Chandrasekharappa S, Burns A, Collins F, Spiegel A, Marx S: Menin molecular interactions: insights into normal functions and tumorigenesis. Horm Metab Res 2005;37:369–374.
5.
Moore PS, Beghelli S, Zamboni G, Scarpa A: Genetic abnormalities in pancreatic cancer. Mol Cancer 2003;2:7–12.
6.
Speel EJM, Scheidweiler AF, Zhao J, Matter C, Saremaslani P, Roth J, Heitz PU, Komminoth P: Genetic evidence for early divergence of small functioning and nonfunctioning endocrine pancreatic tumors: gain of 9q34 is an early event in insulinomas. Cancer Res 2001;61:5186–5192.
7.
Chung DC, Smith AP, Louis DN, Graeme-Cook F, Warshaw AL, Arnold AA: Novel pancreatic endocrine tumor suppressor gene locus on chromosome 3p with clinical prognostic implications. J Clin Invest 1997;100:404–410.
8.
Ebrahimi SA, Wang EH, Wu A, Schreck RR, Passaro E Jr, Sawicki MP: Deletion of chromosome 1 predicts prognosis in pancreatic endocrine tumors. Cancer Res 1999;59:311–315.
9.
Hessman O, Lindberg D, Einarsson A, Lillhagen P, Carling T, Grimelius L, Eriksson B, Åkerström G, Wetin G, Skogseid B: Genetic alterations on 3p, 11q13, and 18q in non-familial pancreatic endocrine tumors. Genes Chrom Cancer 1999;26:258–264.
10.
Barghorn A, Speel EJM, Farspour B, Saremaslani P, Schmid S, Perren A, Roth J, Heitz PU, Komminoth P: Putative tumor suppressor loci at 6q22 and 6q23-q24 are involved in the malignant progression of sporadic endocrine pancreatic tumors. Am J Pathol 2001;158:1903–1911.
11.
Missiaglia E, Moore PS, Williamson J, Lemoine NR, Falconi M, Zamboni G, Scarpa A: Sex chromosome anomalies in pancreatic endocrine tumors. Int J Cancer 2002;98:532–538.
12.
Jonkers YMH, Claessen SMH, Perren A, Schmid S, Komminoth P, Verhofstad AA, Hofland LJ, De Krijger RR, Slootweg PJ, Ramaekers FCS, Speel EJM: Chromosomal instability predicts metastatic disease in patients with insulinomas. Endocr Rel Cancer 2005;12:435–447.
13.
Jonkers YMH, Ramaekers FCS, Speel EJM: Molecular alterations during insulinoma tumorigenesis. Biochim Biophys Acta 2007;1775:313–332.
14.
Speel EJM, Richter J, Moch H, Egenter C, Saremaslani P, Rütimann K, Zhao J, Barghorn A, Roth J, Heitz PU, Komminoth P: Genetic differences in endocrine pancreatic tumor subtypes detected by comparative genomic hybridization. Am J Pathol 1999;155:1787–1794.
15.
Arany I, Rady P, Evers BM, Tyring SK, Townsend CM Jr: Analysis of multiple molecular changes in human endocrine tumors. Surg Oncol 1994;3:153–159.
16.
Evers BM, Ishizuka J, Townsend CM Jr, Thompson JC: The human carcinoid cell line, BON: a model system for the study of carcinoid tumors. Ann NY Acad Sci 1994;733:393–406.
17.
Lankat-Buttgereit B, Gregel C, Knolle A, Hasilik A, Arnold R, Göke R: Pdcd4 inhibits growth of tumor cells by suppression of carbonic anhydrase type II. Mol Cell Endocrinol 2004;214:149–153.
18.
Stålberg P, Grimfjärd P, Santesson M, Zhou Y, Lindberg D, Gobl A, Öberg K, Westin G, Rastad J, Wang S, Skogseid B: Transfection of the multiple endocrine neoplasia type 1 gene to a human endocrine pancreatic tumor cell line inhibits cell growth and affects expression of JunD, δ-like protein 1/preadipocyte factor-1, proliferating cell nuclear antigen, and QM/Jif-1. J Clin Endocrinol Metabol 2004;89:2326–2337.
19.
Hofsli E, Thommesen L, Yadetie F, Langaas M, Kusnierczyk W, Falkmer U, Sandvik AK, Laegreid A: Identification of novel growth factor-responsive genes in neuroendocrine gastrointestinal tumour cells. Br J Cancer 2005;92:1506–1516.
20.
Vitale G, De Herder WW, Van Koetsveld PM, Waaijers M, Schoordijk W, Croze E, Colao A, Lamberts SWJ, Hofland LJ: Interferon-beta is a highly potent inhibitor of gastroenteropancreatic neuroendocrine tumor cell growth in vitro. Cancer Res 2006;66:554–562.
21.
Stålberg P, Santesson M, Ekeblad S, Lejonclou MH, Skogseid B: Recognizing genes differentially regulated in vitro by the multiple endocrine neoplasia type 1 (MEN1) gene, using RNA interference and oligonucleotide microarrays. Surgery 2006;140:921–929.
22.
Stålberg P, Lopez-Edigo JR, Wang S, Gobl A, Öberg K, Skogseid B: Differentially expressed cDNAs in PLCβ3-induced tumor suppression in a human endocrine pancreatic tumor cell line: activation of the human mismatch repair protein 3 gene. Biochem Biophys Res Commun 2001;281:227–231.
23.
Wu F, Berstrom M, Stridsberg M, Orlefors H, Eriksson B, Oberg K, Watanabe Y, Langstrom B: Effect of 6-diazo-5-oxo-L-norleucine (DON) on human carcinoid tumor cell aggregates. Anticancer Res 1997;17:2363–2367.
24.
Johansson T: Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 379: Pancreatic Endocrine Tumourigenesis, 2008.
25.
Speel EJM, Van der Ven PFM, Albrechts JCM, Ramaekers FCS, Fürst DO, Hopman AHN: Assignment of the human gene for the sarcomeric M-band protein myomesin (MYOM1) to 18p11.31–p11.32. Genomics 1998;54:184–186.
26.
Speel EJM, Herbergs J, Ramaekers FCS, Hopman AHN: Combined immunocytochemistry and fluorescence in situ hybridization for simultaneous, tricolor detection of cell cycle, genomic, and phenotypic parameters of tumor cells. J Histochem Cytochem 1994;42:961–966.
27.
Mitelman F (ed): ISCN: An International System for Human Cytogenetic Nomenclature. Basel, Karger, 1995.
28.
Macville M, Veldman T, Padilla-Nash H, Wangsa D, O’Brien P, Schröck E, Ried T: Spectral karyotyping, a 24-colour FISH technique for the analysis of chromosomal rearrangements. Histochem Cell Biol 1997;108:299–305.
29.
Macville M, Schröck E, Padilla-Nash H, Keck C, Ghadimi BM, Zimonjic D, Popescu N, Ried T: Comprehensive and definitive molecular cytogenetic characterization of Hela cells by spectral karyotyping. Cancer Res 1999;59:141–150.
30.
Görtz B, Roth J, Speel EJM, Krähenmann A, De Krijger RR, Matias-Guiu X, Muletta-Feurer S, Rütimann K, Saremaslani P, Heitz PU, Komminoth P: MEN 1 gene mutation analysis of sporadic adrenocortical lesions. Int J Cancer 1999;80:373–379.
31.
Muscarella P, Melvin WS, Fisher WE, Foor J, Ellison EC, Herman JG, Schirmer WJ, Hitchcock CL, DeYoung BR, Weghorst CM: Genetic alterations in gastrinomas and nonfunctioning pancreatic neuroendocrine tumors: an analysis of p16/MTS1 tumor suppressor gene inactivation. Cancer Res 1998;58:237–240.
32.
Serrano J, Goebel SU, Peghini PL, Lubensky IA, Gibril F, Jensen RT: Alterations in the p16INK4A/CDKN2A tumor suppressor gene in gastrinomas. J Clin Endocr Metab 2000;85:4146–4156.
33.
Lubomierski N, Kersting M, Bert T, Muench K, Wulbrand U, Schuermann M, Bartsch D, Simon B: Tumor suppressor genes in the 9p21 cluster are selective targets of inactivation in neuroendocrine gastroenteropancreatic tumors. Cancer Res 2001;61:5905–5910.
34.
Chan AO, Kim SG, Bedeir A, Issa JP, Hamilton SR, Rashid A: CpG island methylation in carcinoid and pancreatic endocrine tumors. Oncogene 2003;22:924–934.
35.
Rocco JW, Sidransky D: p16 (MTS-1/CDKN2/INK4A) in cancer progression. Exp Cell Res 2001;264:42–55.
36.
Kim WY, Sharpless NE: The regulation of INK4/ARF in cancer and aging. Cell 2006;127:265–275.
37.
Michaloglou C, Vredeveld LCW, Soengas MS, Denoyelle C, Kuilman T, Van der Horst CMAM, Majoor DM, Shay JW, Mooi WJ, Peeper DS: BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005;436:720–724.
38.
Dannenberg H, Speel EJM, Zhao J, Saremaslani P, van der Harst E, Roth J, Heitz PU, Bonjer HJ, Dinjens WN, Mooi MJ, Komminoth P, De Krijger RR: Losses of chromosome 1p and 3q are early genetic events in the development of sporadic pheochromocytomas. Am J Pathol 2000;157:353–359.
39.
Zhao J, Speel EJ, Muletta-Feurer S, Rutimann K, Saremaslani P, Roth J, Heitz PU, Komminoth P: Analysis of genomic alterations in sporadic adrenocortical lesions. Gain of chromosome 17 is an early event in adrenocortical tumorigenesis. Am J Pathol 1999;155:1039–1045.
40.
Perry A, Gutmann DH, Reifenberger G: Molecular pathogenesis of meningiomas. J Neuro-Oncol 2004;70:183–202.
41.
Attiyeh EF, London WB, Mossé YP, Wang Q, Winter C, Khazi D, McGrady PW, Seeger RC, Look AT, Shimada H, Brodeur GM, Cohn SL, Matthay KK, Maris JM: Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 2005;353:2243–2253.
42.
Stumpf E, Aalto Y, Höög A, Kjellman M, Otonkoski T, Knuutila S, Andersson LC: Chromosomal alterations in human pancreatic endocrine tumors. Genes Chrom Cancer 2000;29:83–87.
43.
Zhao J, Moch H, Scheidweiler AF, Baer A, Schäffer AA, Speel EJM, Roth J, Heitz PU, Komminoth P: Genomic imbalances in the progression of endocrine pancreatic tumors. Genes Chrom Cancer 2001;32:364–372.
44.
Zhao J, De Krijger RR, Meier D, Speel EJM, Saremaslani P, Muletta-Feurer S, Matter C, Roth J, Heitz PU, Komminoth P: Genomic alterations in well-differentiated gastrointestinal and bronchial neuroendocrine tumors (carcinoids). Marked differences indicating diversity in molecular pathogenesis. Am J Pathol 2000;157:1431–1438.
45.
Tönnies H, Toliat MR, Ramel C, Pape UF, Neitzel H, Berger W, Wiedenmann B: Analysis of sporadic neuroendocrine tumors of the enteropancreatic system by comparative genomic hybridization. Gut 2000;48:536–541.
46.
Kytölä S, Höög A, Nord B, Cedermark B, Frisk T, Larsson C, Kjellman M: Comparative genomic hybridization identifies loss of 18q22-qter as an early and specific event in tumorigenesis of midgut carcinoids. Am J Pathol 2001;158:1803–1808.
47.
Beghelli S, Pelosi G, Zamboni G, Falconi M, Iacono C, Bordi C, Scarpa A: Pancreatic endocrine tumors: evidence for a tumor suppressor pathogenesis and for a tumor suppressor gene on chromosome 17p. J Pathol 1998;186:41–50.
48.
Rigaud G, Missiaglia E, Moore PS, Zamboni G, Falconi M, Talamini G, Pesci A, Baron A, Lissandrini D, Rindi G, Grigolato P, Pederzoli P, Scarpa A: High resolution allelotype of nonfunctional pancreatic endocrine tumors: identification of two molecular subgroups with clinical implications. Cancer Res 2001;61:285–292.
49.
Jonkers YMH, Claessen SMH, Perren A, Schmitt AM, Hofland LJ, De Herder W, De Krijger RR, Verhofstad AA, Hermus AR, Kummer JA, Skogseid B, Volante M, Voogd AC, Ramaekers FCS, Speel EJM: DNA copy number status is a powerful predictor of survival in endocrine pancreatic tumor patients. Endocr Relat Cancer 2007;14:769–779.
50.
Duerr EM, Mizukami Y, Ng A, Xavier RJ, Kikuchi H, Deshpande V, Warshaw AL, Glickman J, Kulke MH, Chung DC: Defining molecular classifications and targets in gastroenteropancreatic neuroendocrine tumors through DNA microarray analysis. Endocr Relat Cancer 2008;15:243–256.
51.
Shay JW, Wright WE: Implications of mapping the human telomerase gene (TERT) as the most distal gene on chromosome 5p. Neoplasia 2000;2:195–196.
52.
Sirivatanauksorn V, Sirivatanauksorn Y, Gorman PA, Davidson JM, Sheer D, Moore PS, Scarpa A, Edwards PAW, Lemoine NR: Non-random chromosomal rearrangements in pancreatic cancer cell lines identified by spectral karyotyping. Int J Cancer 2001;91:350–358.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.